TTrialPathMatch Me to Trials
← Back to trials
RecruitingCannabisAbuse LiabilityExperimental Pain in Healthy Human Participants

Repeated CBD Administration and Cannabis Outcomes

Eligible age

18–55 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This outpatient study examines how cannabidiol (CBD) affects the behavioral and pain-relieving effects of cannabis.

Sponsor: Hannah Harris

You may qualify if…

  • ✓ English-speaking, literate adults,
  • ✓ Male or female,
  • ✓ Between the ages of 18-55,
  • ✓ Body Mass Index from 18.5-32.0 kg/m2,
  • ✓ Not currently seeking treatment for cannabis or drug use,
  • ✓ Able to provide written informed consent and perform all study procedures,
  • ✓ If female, a negative pregnancy test and use of an effective form of contraception during study participation (e.g., oral contraceptive, abstinence, barrier method),
  • ✓ Negative urine drug test for drugs of abuse (other than cannabis) prior to every Laboratory Session, and

You may not qualify if…

  • ✕ Physiologic drug dependence on opioids, benzodiazepines, barbiturates, and/or alcohol that would require medical management,
  • ✕ Clinically significant acute medical problem (e.g., infection) or chronic medical problem requiring daily medication or ongoing medical care (e.g., hypertension, cardiovascular disease, diabetes, respiratory disorders \[e.g., asthma, COPD\]),
  • ✕ Current or past history of major psychiatric disorder that would limit ability to participate in the study,
  • ✕ Use of cannabis exclusively for medical reasons (no recreational use reported),
  • ✕ Current, unrelenting chronic pain that prevents participation (i.e., unable to sit in chair for 8 hours),
  • ✕ Currently using daily prescription medications to manage medical conditions or any drug that could interfere with the study, including potent CYP2C9, CYP3A4, or CYP2C19 inducers,
  • ✕ Clinically significant abnormal ECG (as determined by study physician/cardiologist),
  • ✕ Clinically significant abnormal laboratory findings,

Where it's recruiting

Kentucky

Lexington

Source: ClinicalTrials.gov · NCT07434895 · last updated 2026-08-12

Repeated CBD Administration and Cannabis Outcomes · TrialPath